68 results about "Peritonitis" patented technology

The invention relates to medical instruments, in particular to a peritoneal dialysis device which comprises a dialysate management unit, a sensor unit, a processor, a storage device, a peritoneal transfer model, an intelligent alarm management unit and a communication unit, and the dialysate management unit is configured to be used for perfusion of dialysate into the abdominal cavity of a patient and drainage of the dialysate from the abdominal cavity of the patient; the sensor unit is configured to be used for monitoring physiological parameters of a patient and dialysate characteristic parameters and receiving symptom information and comfort level scores input by the patient, the storage stores instructions executed by the processor, and the instructions enable the processor to be capable of dynamically adjusting treatment parameters of the dialysate management unit in real time in combination with a pre-trained peritoneal transfer model. The perfusion speed, the drainage speed or the dialysate temperature of the dialysate management unit are dynamically adjusted, so that the comfort level score of the patient is maintained to be above a preset threshold value, treatment parameters can be dynamically adjusted in real time to optimize the treatment effect, peritonitis risks are early warned, and the comfort level of the patient is improved.

The invention provides a portable detection device and method for rapidly identifying peritonitis, and relates to the technical field of medical instruments, the device comprises: an illumination module for irradiating a peritoneal dialysis liquid sample; the sensor module is used for capturing a sensing data set of the state change of the peritoneal dialysis liquid sample in the irradiation process; the detection chip downloads the trained peritonitis risk detection model, performs data detection on the sensing data set and outputs a risk detection result; and the display module is used for displaying on a display screen. The peritonitis risk detection device can solve the technical problem that a user is difficult to independently complete rapid and accurate detection in a family or community environment due to poor portability and complex operation of a traditional peritonitis detection device, and achieves the purposes of rapidly analyzing a peritonitis sample through optical characteristics and a machine learning algorithm, outputting a peritonitis risk detection result in real time and improving the detection efficiency. And the accuracy and the efficiency of early peritonitis recognition of the user or the medical personnel are improved.

The invention relates to the technical field of mRNA vaccines, and discloses a feline infectious peritonitis mRNA vaccine as well as a preparation method and application thereof. The feline infectious peritonitis mRNA vaccine comprises mRNA molecules; the mRNA molecule comprises an FIBV-S protein coding sequence as shown in SEQ ID NO: 6. According to the invention, the mRNA sequence for coding the natural FIBV-S protein is modified, so that the FIBV-S protein obtained by translation can be stably maintained at the prefusion conformation and has higher immunogenicity, thereby endowing the mRNA vaccine with a better immune effect and being beneficial to the prevention of feline infectious peritonitis.

The invention discloses application of N4-hydroxycytidine and a derivative thereof in preparation of a medicine for treating cat abdominal infection. The test result shows that the N4-hydroxycytidine and the derivative thereof have a very small toxic effect on normal cat cells, have an obvious inhibiting effect on cat coronavirus (FCoV), and can obviously reduce the virus titer of the virus in the cells. Therefore, the N4-hydroxycytidine and the derivative thereof can be used for preparing a feline coronavirus inhibitor for treating feline infectious peritonitis, and are good in curative effect and high in safety.

The invention belongs to the technical field of medicines, and provides a compound for inhibiting virus replication and application of the compound in preparation of a medicine for resisting feline infectious peritonitis virus (FIPV). The number of the compounds provided by the invention is 10, and the 10 compounds have obvious inhibiting and blocking effects on a 1-bit ribosome frameshift process of the FIPV, and can effectively inhibit the replication and proliferation of the FIPV. The ten compounds can be used for treating and preventing feline infectious peritonitis diseases caused by FIPV infection; the compound disclosed by the invention can be used for preparing anti-FIPV medicines and medicines for treating and preventing feline infectious peritonitis diseases caused by FIPV infection, and has a wide application prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to a nanometer antibody aiming at feline infectious peritonitis virus and application of the nanometer antibody. According to the invention, specific nano antibodies 2S-29 and 2S-39 of two novel FIPV S proteins are obtained by screening through a phage display technology, and a double-antibody sandwich ELISA method for detecting FIPV S antigens is provided. The two antibodies have excellent specificity and affinity to the feline infectious peritonitis virus FIPV S protein. A double-antibody sandwich ELISA method established based on the nano antibody has good specificity, repeatability and sensitivity, the lowest detection limit reaches 4 ng / mL, the FIPV S antigen can be rapidly and accurately detected, and a reliable means is provided for early diagnosis of feline infectious peritonitis.

The invention discloses a cat infectious peritonitis virus isolate and application thereof. The cat infectious peritonitis virus is separated from the peritoneal fluid of a 6-month-old female gradient silver cat, the preservation number of the cat infectious peritonitis virus is CGMCC (China General Microbiological Culture Collection Center) No.46420, and the name of the cat infectious peritonitis virus is SHAANXI-FIBV-II-2024. An animal model is successfully established by using the strain.

This invention provides a saRNA vaccine for the prevention of feline infectious peritonitis (FIP). The saRNA vaccine is a composition comprising saRNA A and saRNA B. The assembly elements of the saRNA include: a 5′ UTR, replicases nsp1-nsp4, a subgenomic promoter, a Kozak sequence, nucleic acid sequence A or nucleic acid sequence B, a 3′ UTR, and a polyadenylated tail (polyA). The saRNA vaccine provided by this invention is effective for the immunization prophylaxis of FIP types I and II. Furthermore, based on the development of this vaccine, by replacing the coding sequences of different antigens, it can be extended to the development of vaccines for other coronaviruses or other veterinary pathogens, demonstrating significant technological transfer value and industrialization prospects.

The utility model discloses a peritoneal dialysis catheter external tube air recognition automatic closing device, which relates to the technical field of medical instruments and comprises a packaging box, a box cover is arranged at the upper end of the packaging box, an external tube is fixedly connected to one side of the packaging box, an inner cylinder is arranged at the position, located in the packaging box, of the external tube, a mounting opening is formed in one side of the inner cylinder, and the outer tube is fixedly connected with the packaging box. A mounting opening is formed in the packaging box, a pressure sensor used for detecting the internal pressure of the inner barrel is mounted in the mounting opening, an electromagnetic valve is further mounted at the position, located in the packaging box, of the external connecting pipe, a microcontroller is arranged in the packaging box, and the electromagnetic valve and the pressure sensor are both electrically connected with the microcontroller. When the device works, once air is detected to enter, the device can automatically trigger a clamping mechanism to effectively prevent the air from entering the abdominal cavity, so that the risk of serious complications such as peritonitis and the like is remarkably reduced.

The invention discloses application of ailanone in preparation of a medicine for treating feline infectious peritonitis, and belongs to the field of biological medicine. The change of the expression quantity of the feline infectious peritonitis virus N protein is detected through indirect immunofluorescence and western blot, and the change of the quantity titer of the feline infectious peritonitis virus is detected through TCID50. Results show that ailanone has an obvious effect of resisting the feline infectious peritonitis virus, the inhibitory effect on the feline infectious peritonitis virus is enhanced along with increase of the drug concentration, and the half effective concentration is 0.09 mu M. Meanwhile, drug inhibition tests show that ailanone has no inhibition effect on feline calicivirus. The invention provides a novel therapeutic drug and strategy for treating feline infectious peritonitis.

The present application relates to the field of medical devices, and discloses a peritoneal dialysis patient peritonitis early warning device based on microfluidic technology, comprising a peritoneal dialysis external catheter and a microfluidic detection module; the peritoneal dialysis external catheter comprises a main passage for dialysis liquid infusion or dialysis waste liquid drainage, and a detection branch selectively communicated with the main passage; a flow path switching structure is arranged on the peritoneal dialysis external catheter, and the flow path switching structure is used for switching between a normal state and a detection state. In the present application, the detection branch selectively communicated with the main passage is arranged on the peritoneal dialysis external catheter, and the flow path switching structure is used for switching between the normal state and the detection state, so that the dialysis waste liquid can enter the microfluidic detection module for detection while maintaining the drainage of the main passage, in-situ detection is realized without changing the basic operation process of peritoneal dialysis, and good clinical process compatibility is achieved.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

An object of the present invention is to provide a therapeutic agent for carcinomatous peritonitis. According to the present invention, there can be provided a therapeutic agent for carcinomatous peritonitis containing an antibody that recognizes the transferrin receptor.

This invention discloses an automatic disinfection and connection device and method for peritoneal dialysis connectors. The device includes a housing containing a cap-pulling baffle, a hook, a cap-spinning baffle, a cap-removing assembly, a first clamping assembly, a multi-directional moving module, an iodine cap clamp, and a second clamping assembly. The housing also contains an ultraviolet disinfection assembly and a control circuit board. This automatic disinfection and connection device for peritoneal dialysis connectors improves the docking methods for double and short tubes, the cap removal method for silicone caps, and the loading and unloading method for iodine caps. It can automatically complete connector docking and separation operations, and can also automatically remove and replace iodine caps, greatly reducing manual operation, lowering the risk of infection caused by human intervention, reducing the occurrence of peritonitis, and improving the safety and standardization of patients' self-use of peritoneal dialysis connector connection devices.

The invention belongs to the fields of traditional Chinese medicines and proteins, provides application of Xiaochaihu decoction in preparation of a medicine for treating peritoneal dialysis related peritonitis, and identifies various antibacterial and immunomodulatory peptides from the Xiaochaihu decoction. The application proves that the common goldenrop decoction has a remarkable adjuvant therapy effect on peritoneal dialysis related peritonitis, and the antibacterial and immunomodulatory polypeptide identified on the basis has remarkable antibacterial and immunomodulatory activity, so that a good basis is provided for further development of medicines.

The application provides a joint conversion connecting device for peritoneal dialysis, and belongs to the technical field of medical equipment. The joint conversion connecting device for peritoneal dialysis comprises a pipeline assembly and a conversion assembly. The pipeline assembly comprises an external short pipe body, an iodophor cap body, a human body end joint body and a protective cover body. The surface of the external short pipe body is provided with a first fastening part. The end of the external short pipe body is provided with a first threaded connector. The surface of the iodophor cap body is provided with a second fastening part. The connecting end of the iodophor cap body is provided with a first groove. The joint in the closed shell is automatically switched and screwed. The joint connecting part does not need to be contacted by hands in the whole process. The peritonitis infection risk in the peritoneal dialysis liquid replacement process is greatly reduced. The external short pipe body, the iodophor cap body and the human body end joint body of the pipeline assembly all adopt the clinical general screw thread interface standard. A special dialysis liquid joint is not needed. The adaptability is strong. The defect that the generality of the prior art is poor is solved.

This application provides a selective HDAC6 inhibitor, its preparation method, and its application, belonging to the field of medicinal chemistry. The selective HDAC6 inhibitor is a compound of Formula I or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, and L are as described herein. The compound of Formula I is a highly selective histone deacetylase 6 (HDAC6) inhibitor, which can be used for diseases caused by HDAC6 abnormalities, such as inflammatory diseases (e.g., peritonitis, inflammatory bowel disease, psoriasis) and other diseases.

Provided is a pharmaceutical preparation, the pharmaceutical preparation comprising: a nucleic acid fragment, the nucleic acid fragment being mRNA, the nucleic acid fragment comprising at least one of a first nucleic acid fragment, a second nucleic acid fragment and a third nucleic acid fragment; the first nucleic acid fragment encodes M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes N protein of feline infectious peritonitis virus; the third nucleic acid fragment encodes S, Sec or SII protein of the feline infectious peritonitis virus; the first nucleic acid fragment, the second nucleic acid fragment and the third nucleic acid fragment are connected or not connected.

The peritoneal dialysis catheter protective sleeve comprises a flexible sleeve, a first opening and a second opening are formed in the two ends of the flexible sleeve in the length direction of the flexible sleeve respectively, a notch extending in the length direction of the sleeve is formed in the peripheral wall of the sleeve, and the sleeve can deform to expand the notch. The first opening is used for allowing the dialysis catheter to penetrate through, the second opening is used for allowing the titanium connector to penetrate through, a positioning groove is formed in the inner circumferential wall of the second opening, and the positioning groove is used for being matched with a concave part of an external short pipe. According to the peritoneal dialysis catheter, it can be guaranteed that the joint of the titanium connector and the peritoneal dialysis catheter is not prone to being folded and bent, abrasion of the titanium connector and the peritoneal dialysis catheter is prevented, and therefore the peritoneal dialysis catheter is protected against breakage and seepage, and peritonitis is avoided. Meanwhile, the positioning groove is matched with the concave part of the external short pipe, so that the external short pipe can be protected from falling off due to various accidents to a certain extent.

The invention relates to the technical field of veterinary drugs, and particularly provides a polynucleotide molecule composition for preventing cat infectious peritonitis, a chimeric polynucleotide molecule and an mRNA vaccine. In order to overcome the ADE effect caused by S protein full-length antigen in the prior art, FIPV N protein without ADE risk is adopted and is combined with screened S protein specific T cell and B cell epitopes. Core schemes include two classes: one is a separate polynucleotide composition comprising epitope peptides encoding N and S proteins; and 2, a single chimeric polynucleotide encoding N protein and S protein epitope peptides. The polynucleotides are optimized by codons and encapsulated in lipid nanoparticles (LNP) to prepare vaccines. Experiments prove that the vaccine can synergistically stimulate powerful immune response, the survival rate of immune cats is remarkably increased to 80%-100% from standard 40% on the premise that ADE is not caused, and FIP is effectively prevented.

The invention discloses an analysis and evaluation method for a patient to assess peritoneal dialysis infection by himself / herself, and the method comprises the steps: collecting multi-dimensional clinical data through an acute symptom questionnaire system, determining a severity score in combination with abdominal pain, abdominal pain accompanying symptoms and body temperature abnormality indexes, and achieving precise triage. When peritonitis is evaluated, the traits of the peritoneal dialysis solution are meticulously analyzed, and various preliminary diagnosis suggestions can be accurately given; evaluating catheter outlet and tunnel skin, analyzing and judging emergencies according to images, and determining a grading processing decision by using a skin grading system to realize accurate hierarchical management. In addition, once the infection or emergency risk is judged, treatment prompt information can be output in time, so that the patient can see a doctor in time and grasp the optimal treatment opportunity, and disease delay is reduced. According to the scheme, the evaluation accuracy is improved, the patient can be assisted in evaluating the infection condition and the treatment effect in real time, medical staff can be helped to scientifically and normatively extract and conclude patient infection related data, and therefore accurate layered management on the infection risk degree is achieved.

The present invention relates to a peritoneal dialysis system having a sensor and configured for diagnosing peritonitis. Peritoneal dialysis, such as automated peritoneal dialysis ("APD"), is equipped with one or more or all of the following sensing or feedback features: impedance sensing for detection of peritonitis, temperature sensing for detection of peritonitis, biological MEMS sensing for detection of peritonitis, and glycemic control for diabetic patients, each sensing or feedback feature analyzes the patient's effluent liquid or liquid residing within the patient's abdominal cavity.

The present invention provides a system and a method for monitoring Peritoneal dialysis (PD) effluent to determine peritonitis condition using a machine learning model. The system comprises a user input device configured to upload at least one image of the peritoneal dialysis (PD) effluent bag and an image processing server having a processor configured to receive at least one image from the input device, process the received image of the PD effluent bag, by a convolutional neural network (CNN) model and classify the processed received image in one or more category of infection levels. The system further comprises an output device coupled to the image processing server and is configured to output the category of an infection level based on the processing of the image from the input device. Further, the processor is configured to create a training dataset from a plurality of images of the peritoneal dialysis (PD) effluent bag having an effluent density with varying colour gradient, train the convolutional neural network (CNN) model, with the plurality of the images of the PD effluent bag and classify the images of the PD effluent, with one or more category of the infection level.

The invention relates to application of a gold preparation in preparation of a medicine for treating feline infectious peritonitis. The gold preparation provided by the invention comprises a gold nanocluster, gold nanoparticles, a gold nofen molecule and a glucosinolate gold molecule. The invention finds and verifies that the provided gold preparation can inhibit inflammation caused by feline infectious peritonitis (FIP) for the first time, effectively controls the progress of FIP, remarkably improves the survival rate and life quality of sick animals, provides a new FIP treatment strategy with low cost and high potential for animal clinic, and has a wide application prospect. The application blank of the gold preparation in the field of veterinary medicine FIP treatment is creatively filled up.

The invention discloses a peritoneal dialysis related peritonitis patient treatment failure risk prediction method, and relates to the technical field of intelligent medical information processing, and the method comprises the steps: carrying out the key feature screening based on a patient standardized spatio-temporal feature vector set, simulating the evolution trajectory under different clinical conditions through an anti-fact sample, and carrying out the prediction of the treatment failure risk of a peritoneal dialysis related peritonitis patient. Generating an anti-fact disease course evolution trajectory data set; performing feature fusion on the anti-fact disease course evolution trajectory data set and multi-source clinical data by adopting time window splicing and multi-dimensional alignment to form a three-dimensional fusion feature tensor with a time dimension, a feature dimension and a scene dimension; carrying out entropy risk assessment by using the three-dimensional fusion feature tensor, and obtaining a dynamic treatment failure risk value; and carrying out risk state division according to the dynamic treatment failure risk value, and generating an individualized risk prediction result and an intervention prompt. According to the method, the complexity and uncertainty of the course of disease are effectively quantified, and dynamic and accurate risk early warning and decision support are provided for clinic.

This disclosure relates to the development of a multi-antigen mRNA vaccine against feline infectious peritonitis virus (FIPV). Provided is a pharmaceutical formulation. The pharmaceutical formulation includes a nucleic acid fragment. The nucleic acid fragment is mRNA and includes at least one of a first nucleic acid fragment, a second nucleic acid fragment, or a third nucleic acid fragment. The first nucleic acid fragment encodes an M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes an N protein of feline infectious peritonitis virus; the third nucleic acid fragment encodes an S protein, an S_ec protein, or an SII protein of feline infectious peritonitis virus; and the first nucleic acid fragment, the second nucleic acid fragment, and the third nucleic acid fragment are linked or not linked.

The invention discloses a pharmaceutical composition for cat infectious peritonitis. The pharmaceutical composition comprises or is prepared from the following components: GS-441524 or pharmaceutically acceptable salt thereof, a solubilizer, an acid-base regulator and water. The high solubility of the GS-441524 can be effectively maintained in a relatively high pH value range (2 to 4), so that the stability and the injection safety of the GS-441524 are improved.

A cerium oxide nanocomplex, a composition containing the cerium oxide nanocomplex as an active ingredient, and uses thereof for preventing or treating peritonitis are disclosed. The cerium oxide nanocomplex improves the biomedical stability, biocompatibility, and efficiency of the production process of nanoparticles while maintaining the excellent inhibitory activity against inflammation by applying a biocompatible polymer composed of an optimal combination. The cerium oxide nanocomplex may be used as an excellent therapeutic composition that may greatly improve patients' survival rate by effectively inhibiting inflammatory response and quickly blocking tissue damage at early stage of peritonitis when a radical inflammatory injury occurs because of the penetration of bacteria, foreign body and immune cells into a perforated organ in the abdominal cavity.

The present invention discloses the application of SB-222200 in inhibiting the activation of NLRP3 inflammasome. This SB-222200 can specifically inhibit the activation of NLRP3 inflammasome, and the inhibition of NLRP3 inflammasome activation does not depend on the antagonism of NK3 receptor. SB-222200 inhibits the assembly of NLRP3 inflammasome by directly binding to NLRP3 protein, and also inhibits the oligomerization and speck formation of ASC protein during the activation of NLRP3 inflammasome, inhibits the cleavage of GSDMD and the pyroptosis caused by it, inhibits the oligomerization of NLRP3 protein itself and the interaction between NLRP3 protein and ASC protein; meanwhile, this SB-222200 can also alleviate peritonitis and inflammatory bowel disease. It can be used as a potential drug for preventing and / or treating diseases related to abnormal activation of NLRP3 inflammasome.

The invention relates to the technical field of medical monitoring, and discloses an artificial intelligence peritonitis monitoring device, system and method, and the device comprises a closed darkroom, a high-transparency pipeline, a simulated natural light source, a color sensor, a parallel light source, a light sensor, an opaque partition plate and an intelligent chip; the closed darkroom is divided into an upper color monitoring area and a lower turbidity monitoring area through a non-transparent partition plate, and the high-transparency pipeline vertically penetrates through the non-transparent partition plate and is communicated with the drainage end of the peritoneal dialysis pipeline and a waste liquid barrel; the intelligent chip is connected with the color sensor and the light sensor, an artificial intelligence algorithm is built in the intelligent chip, the intelligent chip carries out noise suppression by constructing a four-dimensional Kalman filtering state vector containing RGB three-primary color components and turbidity, peritonitis risk judgment is carried out based on fusion data of dialysate optical characteristics and patient information, and the peritonitis risk judgment result is obtained. Peritonitis recognition sensitivity is not less than 95%, specificity is not less than 99%, and accuracy is not less than 98%; the problem of single detection dimension is solved, and accurate support is provided for early warning.